相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Reactions Related to CAR-T Cell Therapy
Lele Miao et al.
FRONTIERS IN IMMUNOLOGY (2021)
Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer
Prahlad V. Raninga et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Peter Braendstrup et al.
CYTOTHERAPY (2020)
Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin
Amir Ata Saei et al.
REDOX BIOLOGY (2020)
The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Liam Baird et al.
MOLECULAR AND CELLULAR BIOLOGY (2020)
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination
Tanja Lovgren et al.
ONCOIMMUNOLOGY (2020)
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells
Paramita Chakraborty et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
Karl E. Carlstrom et al.
NATURE COMMUNICATIONS (2019)
Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial
Ricardo Sobhie Diaz et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Therapeutic targeting of the NRF2 and KEAP 1 partnership in chronic diseases
Antonio Cuadrado et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The thioredoxin reductase inhibitor auranofin induces heme oxygenase-1 in lung epithelial cells via Nrf2-dependent mechanisms
Katelyn Dunigan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2018)
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function
Andrew Stiff et al.
CLINICAL CANCER RESEARCH (2018)
Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer
Takeshi Ishikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Reactive oxygen species in haematopoiesis: leukaemic cells take a walk on the wild side
Rodrigo Prieto-Bermejo et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
KEAP1 Editing Using CRISPR/Cas9 for Therapeutic NRF2 Activation in Primary Human T Lymphocytes
Sanjeev Noel et al.
JOURNAL OF IMMUNOLOGY (2018)
High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
Carsten Krieg et al.
NATURE MEDICINE (2018)
Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy
William C. Stafford et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Viktor Fleming et al.
FRONTIERS IN IMMUNOLOGY (2018)
Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements (vol 36, pg 765, 2018)
Michael Kosicki et al.
NATURE BIOTECHNOLOGY (2018)
Cross Talk in HEK293 Cells Between Nrf2, HIF, and NF-κB Activities upon Challenges with Redox Therapeutics Characterized with Single-Cell Resolution
Katarina Johansson et al.
ANTIOXIDANTS & REDOX SIGNALING (2017)
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Maarten A. Ligtenberg et al.
JOURNAL OF IMMUNOLOGY (2016)
Retuning of Mouse NK Cells after Interference with MHC Class I Sensing Adjusts Self-Tolerance but Preserves Anticancer Response
Arnika Kathleen Wagner et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors
Anju Singh et al.
ACS CHEMICAL BIOLOGY (2016)
PARADOXICAL ROLES OF ANTIOXIDANT ENZYMES: BASIC MECHANISMS AND HEALTH IMPLICATIONS
Xin Gen Lei et al.
PHYSIOLOGICAL REVIEWS (2016)
TrxR1 as a Potent Regulator of the Nrf2-Keap1 Response System
Marcus Cebula et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Douglas Marvel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
T Lymphocyte-Specific Activation of Nrf2 Protects from AKI
Sanjeev Noel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
First-in-Man Clinical Results With Good Manufacturing Practice (GMP)-compliant Polypeptide-expanded Adenovirus-specific T Cells After Haploidentical Hematopoietic Stem Cell Transplantation
Rene Geyeregger et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes
Marcel Deponte
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2013)
The biological activity of auranofin: implications for novel treatment of diseases
J. M. Madeira et al.
INFLAMMOPHARMACOLOGY (2012)
Inhibition of Superoxide Generation upon T-Cell Receptor Engagement Rescues Mart-127-35-Reactive T Cells from Activation-Induced Cell Death
Hakan Norell et al.
CANCER RESEARCH (2009)
Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells
Shinha Han et al.
ARCHIVES OF PHARMACAL RESEARCH (2008)
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Xiao-Jun Wang et al.
CARCINOGENESIS (2008)
Transduction with the Antioxidant Enzyme Catalase Protects Human T Cells against Oxidative Stress
Takashi Ando et al.
JOURNAL OF IMMUNOLOGY (2008)
The CD16-CD56bright NK cell subset is resistant to reactive oxygen species produced by activated Granulocytes and has higher antioxidative capacity than the CD16+CD56dim subset
Helena Harlin et al.
JOURNAL OF IMMUNOLOGY (2007)
Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial
Mats Brune et al.
BLOOD (2006)
Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy
Y Hamaguchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species
S Kusmartsev et al.
JOURNAL OF IMMUNOLOGY (2004)
Emerging insights into the biology and therapy of malignant mesothelioma
NJ Vogelzang
SEMINARS IN ONCOLOGY (2002)
Reactive oxygen species, antioxidants, and the mammalian thioredoxin system
J Nordberg et al.
FREE RADICAL BIOLOGY AND MEDICINE (2001)
分享论文
